AU-011 is made up of viral nanoparticles which latch onto and, once activated by an ophthalmic laser, kill cancer cells in the back of the eye.
Importantly, they do this without damaging the surrounding tissue, preserving patients’ vision.
Brian Marr, the trial’s principal investigator, said: “These 12-month data demonstrate that light-activated AU-011 continues to be well-tolerated, including with multiple administrations, has evidence of tumour control and preservation of visual acuity”
Arix chief investment officer Joe Anderson added: “We believe that this minimally invasive, non-radiation-based treatment option, has the potential to offer a new treatment option for patients.”
“We continue to support Aura as the company progresses towards a pivotal phase III study.”
Arix, which has a 6.6% stake in Aura, saw its shares drop 4.1% to 162.6p in late-afternoon trading.